Skip to main content

RTI, PierianDx Collaborate on Clinical Genomics Platform

NEW YORK (GenomeWeb) – RTI International and PierianDx today announced a strategic collaboration to accelerate the impact and adoption of PierianDx's genomics platform.

The collaboration includes an undisclosed investment and other strategic support to help advance PierianDx's growth plan, the firms said.

Since 2014, PierianDx has focused on providing solutions to accelerate molecular testing to advance precision medicine and has built the Clinical Genomics WorkSpace, a clinical genomics platform that creates streamlined analysis, interpretations, and reporting for clinical labs, the firms said.

By integrating cloud-based software and clinical lab enablement services, the platform simplifies the translation of genomic data into patient-specific diagnoses and treatments, the firms said. The PierianDx Partner Sharing Network consists of more than 50 members, including academic medical centers, cancer centers, and health systems that utilize shared genomic data to target patient-specific diagnoses and treatments for cancers and hereditary diseases.

Matt Jenkins, vice president and head of corporate development at RTI, said in a statement that RTI hopes to contribute its "expertise and resources to accelerate PierianDx's impact and adoption of its genomics platform."